The story of the erectile dysfunction drug presents a challenging picture for investors. While the initial launch generated substantial profits, the end of its patent opened the door to cheaper versions, dramatically https://socialwebconsult.com/story7140189/viagra-and-big-pharma-a-volatile-investment